Young Jun Kim

Young Jun Kim

Auto-generated profile, based on publicly available information

Young Jun Kim

Medical Metrology Group, Korea Research Institute of Standards and Science, Daejeon, 34113, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2017 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Yoon-Tae KangYoon-Tae Kang
Yoon-Tae Kang
YKYoung Jun Kim
Young Jun Kim
JBJiyoon Bu
Jiyoon Bu
Youngho ChoYoungho Cho
Youngho Cho
SHSae-Won Han
Sae-Won Han
BMByung-In Moon
Byung-In Moon
We present a microfluidic device for the capture and release of circulating exosomes from human blood. The exosome-specific dual-patterned immunofiltration (ExoDIF) device is composed of two distinct immuno-patterned layers, and is capable of enhancing the chance of binding between the antibody and exosomes by generating mechanical whirling, thus achieving high-throughput exosome isolation with high specificity. Moreover, follow-up recovery after the immuno-affinity based isolation, via cleavage of a linker, enables further downstream analysis. We verified the performance of the present device using MCF-7 secreted exosomes and found that both the concentration and proportion of exosome-sized vesicles were higher than in the samples obtained from the conventional exosome isolation kit. We then isolated exosomes from the human blood samples with our device to compare the exosome level between cancer patients and healthy donors. Cancer patients show a significantly higher exosome level with higher selectivity when validating the exosome-sized vesicles using both electron microscopy and nanoparticle tracking analysis. The captured exosomes from cancer patients also express abundant cancer-associated antigens, the epithelial cell adhesion molecule (EpCAM) on their surface. Our simple and rapid exosome recovery technique has huge potential to elucidate the function of exosomes in cancer patients and can thus be applied for various exosome-based cancer research studies.

28 January 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
JSJae-Eul Shim
Jae-Eul Shim
YKYoung Jun Kim
Young Jun Kim
EHEunil Hahm
Eunil Hahm
JCJong-Ho Choe
Jong-Ho Choe
ABAhruem Baek
Ahruem Baek
EYEun-Ah You
Eun-Ah You
Alzheimer's disease (AD) is a severe neurodegenerative disease that requires early diagnosis to manage its progression. Although the simultaneous detection of multiple AD biomarkers is expected to facilitate early assessment of AD risk, the lack of multiplexed sensing platforms for accurately quantifying multiple AD biomarkers remains a challenge. Here, we present a multiplexed digital sensing platform based on bumpy core-shell (BCS) surface-enhanced Raman spectroscopy (SERS) nanoprobes for ultrasensitive, quantitative, and simultaneous detection of Aβ42 and Aβ40 as AD biomarkers, enabling the accurate determination of the Aβ42/Aβ40 ratio. We synthesized BCS SERS nanoprobes with distinct Raman reporters to generate unique, intense, and reproducible SERS signals, offering single-nanoparticle sensitivity and quantification capabilities. These nanoprobes were subsequently employed in SERS-based immunoassays combined with digital SERS analysis for multiplexed quantification. The proposed platform accurately and quantitatively detected Aβ42 and Aβ40 across a range of five orders of magnitude, with a limit of detection of 8.7× 10-17 g/mL (1.9 × 10-17 M) for Aβ42 and 1.0 × 10-15 g/mL (2.3 × 10-16 M) for Aβ40, surpassing the performance of conventional enzyme-linked immunosorbent assays. Based on the exclusive detection of Aβ42 and Aβ40 using distinct SERS nanoprobes, the proposed sensing platform can also accurately quantify Aβ42 and Aβ40 at clinically relevant levels in both cerebrospinal fluid and blood plasma. Therefore, this sensing platform can be used to accurately and reliably determine the Aβ42/Aβ40 ratio, thus serving as an effective tool for the early diagnosis of AD.

12 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Yoon-Tae KangYoon-Tae Kang
Yoon-Tae Kang
YKYoung Jun Kim
Young Jun Kim
TLTae Hee Lee
Tae Hee Lee
Youngho ChoYoungho Cho
Youngho Cho
HCHee Jin Chang
Hee Jin Chang
HLHyun-Moo Lee
Hyun-Moo Lee
Circulating tumor cells have emerged as biomarkers for estimating the tumor burden and metastatic potential of cancer patients. However, to date, most of studies and applications of circulating tumor cells have been conducted and applied to epithelial cancers such as breast, colorectal, and prostate tumor. The only FDA-cleared method, CellSearch, makes use of antibody against epithelial surface protein expressed on CTCs, thus obstructing wide application for various cancers with non-epithelial and semi-epithelial characteristics including renal cell carcinoma. Due to rarity and ambiguity of CTCs, designed experiment including non-biased CTC isolation and subsequent cytopathological study for finding applicable immunomarkers are urgently needed for clinical use of CTCs for less-studied cancers. Here, in order to construct the fundamental step for CTC diagnosis without limitation of its epithelial characteristics, we present the simple and novel method which incorporate both label-free CTC isolation and pathological study using hydrogel-based cell block formation. Six cell lines from lung, ovarian, kidney cancers were used to make cell block and analyzed by conventional immunocytochemical staining method to find the candidate markers for CTC. Especially for renal cancer, the physically isolated CTCs were further immunocytochemically examined with the screened candidate markers by cell block construction, and verified their clinical utility using blood samples from patients with renal cell carcinoma. This comprehensive study demonstrates that the present approach can be used to find the potential markers for any type of cancers regardless of their epithelial characteristics and isolate the specific type of CTCs in label-free manners.

18 December 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
YKYoung Jun Kim
Young Jun Kim
Youngho ChoYoungho Cho
Youngho Cho
JMJunhong Min
Junhong Min
SHSae-Won Han
Sae-Won Han